Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis | Zendy

Hamza Hashmi | Zendy; Shruti Bhandari | Zendy; Rohit Kumar | Zendy; Prashant Tripathi | Zendy; Jill Blancett Rhodes | Zendy; Lindsay Figg | Zendy; Timothy Baize | Zendy; Maxwell M. Krem | Zendy; Mohamed Hegazi | Zendy; Robert Emmons | Zendy

Open Access

Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis

Author(s) -

Hamza Hashmi,

Shruti Bhandari,

Rohit Kumar,

Prashant Tripathi,

Jill Blancett Rhodes,

Lindsay Figg,

Timothy Baize,

Maxwell M. Krem,

Mohamed Hegazi,

Robert Emmons

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.03.002

Subject(s) - tacrolimus , medicine , toxicity , dosing , bolus (digestion) , graft versus host disease , clinical endpoint , regimen , gastroenterology , transplantation , surgery , anesthesia , clinical trial

Among patients undergoing allogeneic hematopoietic cell transplant, continuous intravenous (IV) tacrolimus infusion is frequently used for graft-versus-host disease (GvHD) prophylaxis. Twice-daily intermittent IV tacrolimus dosing may confer safety and convenience benefits.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research